Results 91 to 100 of about 29,353 (245)
Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. [PDF]
, 2019 Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have ...
Dulawa, Stephanie C, Janowsky, David S
core
Interactions between the neuromodulatory systems and the amygdala: exploratory survey using the Allen Mouse Brain Atlas. [PDF]
, 2013 Neuromodulatory systems originate in nuclei localized in the subcortical region of the brain and control fundamental behaviors by interacting with many areas of the central nervous system.
Krichmar, Jeffrey L, Zaldivar, Andrew
core +1 more source
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
British Journal of Pharmacology, EarlyView.Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
Central Executive Dysfunction and Deferred Prefrontal Processing in Veterans with Gulf War Illness. [PDF]
, 2013 Gulf War Illness is associated with toxic exposure to cholinergic disruptive chemicals. The cholinergic system has been shown to mediate the central executive of working memory (WM).
Bennett, Ilana J +7 more
core +2 more sources
Glial cells in the heart: Implications for their roles in health and disease
The Journal of Physiology, EarlyView.Abstract figure legend Schematic representation of cardiac autonomic ganglia within epicardial fat pads (posterior heart surface shown), containing vagal postganglionic neuron cell bodies, associated fibres, and glia. These ganglia receive cholinergic input from vagal preganglionic neurons and adrenergic input from sympathetic postganglionic neurons ...
Svetlana Mastitskaya +2 more
wiley +1 more source
Functional Analysis of Transmembrane Domain 2 of the M1 Muscarinic Acetylcholine Receptor [PDF]
Journal of Biological Chemistry, 2007 Ala substitution scanning mutagenesis has been used to probe the functional role of amino acids in transmembrane (TM) domain 2 of the M1 muscarinic acetylcholine receptor, and of the highly conserved Asn43 in TM1. The mutation of Asn43, Asn61, and Leu64 caused an enhanced ACh affinity phenotype. Interpreted using a rhodopsin-based homology model, these
Mark S, Bee, Edward C, Hulme
openaire +2 more sources
Food Science &Nutrition, Volume 14, Issue 2, February 2026.Atractylone exhibits diverse pharmacological effects, including anticancer and neuroprotection. A systematic review was conducted following PRISMA guidelines to analyze Atractylone. This study explores Atractylone's sources, biosynthesis, and therapeutic potential.
Hamza Elhrech +8 more
wiley +1 more source
MedComm, Volume 7, Issue 2, February 2026.Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo +11 more
wiley +1 more source
Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors. [PDF]
PLoS ONE, 2014 Xanomeline is an agonist endowed with functional preference for M1/M4 muscarinic acetylcholine receptors. It also exhibits both reversible and wash-resistant binding to and activation of these receptors.
Eva Šantrůčková +3 more
doaj +1 more source
Enhancing remyelination in multiple sclerosis via M1 muscarinic acetylcholine receptor
Molecular PharmacologyMultiple sclerosis (MS) is growing in prevalence; yet, treatments that can reverse the progression of the disease are still needed. One strategy that has shown promise for reversing MS is remyelination by inhibiting the M1 receptor, a member of the muscarinic acetylcholine receptor (mAChR) family.
Keren Chen +2 more
openaire +2 more sources